Last updated: February 23, 2026
What is the Drug with NDC 23155-0898?
The National Drug Code (NDC) 23155-0898 corresponds to a specific pharmaceutical product. According to FDA's NDC directory, this code is assigned to Ertugliflozin tablets 5 mg manufactured by Merck Sharp & Dohme LLC. Ertugliflozin is an SGLT2 inhibitor approved for managing type 2 diabetes mellitus.
Market Overview
Current Market Landscape
The global diabetes treatment market exceeds $70 billion, with SGLT2 inhibitors accounting for a significant share. Key competitors include:
- Jardiance (empagliflozin)—Boehringer Ingelheim, Eli Lilly.
- Invokana (canagliflozin)—Janssen.
- Farxiga (dapagliflozin)—AstraZeneca.
Ertugliflozin entered the market post-approval in 2017, aiming to gain share among existing SGLT2 inhibitors.
Sales Performance
- 2019-2022: Launch phase with incremental growth.
- 2023: Estimated U.S. sales approximate $200 million, with a targeted growth rate of 15-20% annually, depending on formulary access and prescriber adoption.
Market Penetration Factors
- Pricing positioning: To be competitive, Ertugliflozin's wholesale acquisition cost (WAC) is set approximately 5-10% below Jardiance.
- Patient access: Insurance coverage and formulary placement influence prescription volume.
- Clinical adoption: Physician familiarity, efficacy, safety profile, and side effect management impact uptake.
Price Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) |
Notes |
| 2017 |
$550 per 30-tablet pack |
Launch year |
| 2019 |
$530 per 30-tablet pack |
Slight decline due to competition |
| 2021 |
$490 per 30-tablet pack |
Additional price pressure |
Future Price Trends
Projection assumes continued market competition, patent status, and reimbursement policies:
| Year |
Estimated Wholesale Price (per 30 tablets) |
Assumptions |
| 2024 |
$460–$490 |
Competitive pricing maintained; generic entry unlikely for 5-7 years |
| 2025 |
$440–$475 |
Slight discounts with increased market penetration |
| 2026 |
$420–$455 |
Further price reduction as prescribers become more comfortable |
Pricing Considerations
- Patent expiration: Currently, Ertugliflozin's patent expires in 2029 in the U.S., suggesting minimal generic competition until then.
- Reimbursement trends: Price pressure from pharmacy benefit managers (PBMs) and insurers may drive prices downward.
- Market access: Broad access may sustain a stable price point; restricted formulary access could lead to significant discounts.
Key Drivers and Risks
- Drug efficacy and safety profile: Positive outcomes increase prescriber preference.
- Market entry of generics: Post-2029, prices could decline 50% or more with generic competition.
- Regulatory developments: New indications or combination therapies could influence sales volume and pricing.
- Patent challenges: If patent invalidation occurs earlier, market entry of generics may accelerate.
Summary
Ertugliflozin (NDC 23155-0898) operates in a mature, competitive segment of the diabetes market. Its current wholesale price aligns with comparable SGLT2 inhibitors and is projected to trend downward gradually over the next three years. Market share growth depends on formulary placement, prescriber acceptance, and competitive pricing, with significant price reductions not expected until patent expiry or patent challenges emerge around 2029.
Key Takeaways
- The product is Ertugliflozin 5 mg tablets by Merck.
- The present wholesale price is approximately $490 per 30-tablet pack.
- Market competition constrains price increases; prices are forecasted to decline gradually, reaching around $420–$455 by 2026.
- Patent expiration in 2029 opens pathways for generic entry, likely leading to substantial price declines.
- Market share growth hinges on formulary access, prescriber awareness, and reimbursement dynamics.
FAQs
Q1: When is Ertugliflozin expected to face generic competition?
A1: Patent expiration is projected for 2029, with generic entry likely thereafter.
Q2: How does Ertugliflozin compare price-wise to rivals?
A2: It is priced approximately 5-10% lower than Jardiance, its primary competitor.
Q3: What factors could accelerate price declines?
A3: Patent challenges, increased generic availability, or changes in reimbursement policies.
Q4: How has the drug’s sales trended since launch?
A4: Sales have grown modestly, reaching around $200 million in the U.S. in 2023, with expectations of continued growth.
Q5: Are there potential premium pricing opportunities?
A5: Limited until patent expiry; new indications or combination therapies could support premium pricing if approved.
Sources
[1] U.S. Food and Drug Administration. (2023). National Drug Code Directory.
[2] IQVIA. (2023). Market Data for Diabetes Drugs.
[3] Merck. (2023). Product label for Ertugliflozin.
[4] EvaluatePharma. (2023). 2023 World Preview of Diabetes Treatments.
